Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2024 · third_quarter · Q3
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Step Therapy. Telehealth. Priority Review Voucher Reauthorization. H.R.6892: Medical Nutrition Equity Act of 2023.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Source: Senate LDA
Medical Nutrition Equity Act of 2023
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Step Therapy. Telehealth. Priority Review Voucher Reauthorization. H.R.6892: Medical Nutrition Equity Act of 2023.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2024 · second_quarter · Q2
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE